Data completeness
0/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILOSONE SULFA is an oral suspension small-molecule antibiotic combining erythromycin (macrolide) with sulfonamide activity, currently in pre-launch development by Eli Lilly. The product targets bacterial infections susceptible to macrolide-sulfa combination therapy. Patient population and specific indications remain under clinical evaluation.
PRE_LAUNCH
Pre-launch stage requires robust cross-functional teams; team size and commercial investment will depend on regulatory approval timelines and competitive positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ILOSONE SULFA offers career exposure to pre-launch strategy, regulatory navigation of combination therapies, and build-out of commercial infrastructure. Opportunity is high-risk, high-learning; success depends on regulatory clearance and competitive differentiation in a crowded antibiotics market.
Regulatory Affairs ManagerBrand Manager (pre-launch)
Worked on ILOSONE SULFA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.